Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Zepbound® (tirzepatide) – New indication
December 20, 2024 - The FDA announced the approval of Eli Lilly’s Zepbound (tirzepatide), in combination with a reduced-calorie diet and increased physical activity, for treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity.
